Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma

The low resection and high recurrence rates in hepatocellular carcinoma (HCC) are the major challenges to improving prognosis. Neoadjuvant and conversion therapies are underlying strategies to overcome these challenges. To date, no guideline or consensus has been published on the neoadjuvant and con...

Full description

Saved in:
Bibliographic Details
Published inWorld journal of gastroenterology : WJG Vol. 27; no. 47; pp. 8069 - 8080
Main Authors Zhao, Hai-Tao, Cai, Jian-Qiang
Format Journal Article
LanguageEnglish
Published United States Baishideng Publishing Group Inc 21.12.2021
Subjects
Carcinoma, Hepatocellular - therapy
Consensus
Expert Consensus
Humans
Liver Neoplasms - therapy
Neoadjuvant Therapy - adverse effects
Prognosis
Conversion therapy
Neoadjuvant therapy
Hepatocellular carcinoma
Consensus
Online AccessGet full text

Cover

Abstract The low resection and high recurrence rates in hepatocellular carcinoma (HCC) are the major challenges to improving prognosis. Neoadjuvant and conversion therapies are underlying strategies to overcome these challenges. To date, no guideline or consensus has been published on the neoadjuvant and conversion therapies in HCC. Recent studies showed that neoadjuvant therapy for resectable HCC and conversion therapy for unresectable HCC are safe, feasible, and effective. Neoadjuvant and conversion therapies have the following advantages in treating HCC: R0 resection with sufficient volume of future liver remnant, relatively simple operation, and wide applicability. Therefore, it was necessary to conduct a widely accepted consensus among the experts in China who have extensive expertise and experience in treating HCC using neoadjuvant and conversion therapies, which is important to standardize the application of neoadjuvant and conversion therapies for the management of HCC. The strategies of neoadjuvant therapy include the selection of the eligible patients, therapy regimen, cycles, effect evaluations, and multidisciplinary treatment. The management of patients with insufficient volume of future liver remnant and patients who cannot achieve R0 resection is the key to the strategies of conversion therapy. Here, we present the resultant evidence- and experience-based consensus to guide the application of neoadjuvant and conversion therapies in clinical practice.
AbstractList The low resection and high recurrence rates in hepatocellular carcinoma (HCC) are the major challenges to improving prognosis. Neoadjuvant and conversion therapies are underlying strategies to overcome these challenges. To date, no guideline or consensus has been published on the neoadjuvant and conversion therapies in HCC. Recent studies showed that neoadjuvant therapy for resectable HCC and conversion therapy for unresectable HCC are safe, feasible, and effective. Neoadjuvant and conversion therapies have the following advantages in treating HCC: R0 resection with sufficient volume of future liver remnant, relatively simple operation, and wide applicability. Therefore, it was necessary to conduct a widely accepted consensus among the experts in China who have extensive expertise and experience in treating HCC using neoadjuvant and conversion therapies, which is important to standardize the application of neoadjuvant and conversion therapies for the management of HCC. The strategies of neoadjuvant therapy include the selection of the eligible patients, therapy regimen, cycles, effect evaluations, and multidisciplinary treatment. The management of patients with insufficient volume of future liver remnant and patients who cannot achieve R0 resection is the key to the strategies of conversion therapy. Here, we present the resultant evidence- and experience-based consensus to guide the application of neoadjuvant and conversion therapies in clinical practice.
The low resection and high recurrence rates in hepatocellular carcinoma (HCC) are the major challenges to improving prognosis. Neoadjuvant and conversion therapies are underlying strategies to overcome these challenges. To date, no guideline or consensus has been published on the neoadjuvant and conversion therapies in HCC. Recent studies showed that neoadjuvant therapy for resectable HCC and conversion therapy for unresectable HCC are safe, feasible, and effective. Neoadjuvant and conversion therapies have the following advantages in treating HCC: R0 resection with sufficient volume of future liver remnant, relatively simple operation, and wide applicability. Therefore, it was necessary to conduct a widely accepted consensus among the experts in China who have extensive expertise and experience in treating HCC using neoadjuvant and conversion therapies, which is important to standardize the application of neoadjuvant and conversion therapies for the management of HCC. The strategies of neoadjuvant therapy include the selection of the eligible patients, therapy regimen, cycles, effect evaluations, and multidisciplinary treatment. The management of patients with insufficient volume of future liver remnant and patients who cannot achieve R0 resection is the key to the strategies of conversion therapy. Here, we present the resultant evidence- and experience-based consensus to guide the application of neoadjuvant and conversion therapies in clinical practice.The low resection and high recurrence rates in hepatocellular carcinoma (HCC) are the major challenges to improving prognosis. Neoadjuvant and conversion therapies are underlying strategies to overcome these challenges. To date, no guideline or consensus has been published on the neoadjuvant and conversion therapies in HCC. Recent studies showed that neoadjuvant therapy for resectable HCC and conversion therapy for unresectable HCC are safe, feasible, and effective. Neoadjuvant and conversion therapies have the following advantages in treating HCC: R0 resection with sufficient volume of future liver remnant, relatively simple operation, and wide applicability. Therefore, it was necessary to conduct a widely accepted consensus among the experts in China who have extensive expertise and experience in treating HCC using neoadjuvant and conversion therapies, which is important to standardize the application of neoadjuvant and conversion therapies for the management of HCC. The strategies of neoadjuvant therapy include the selection of the eligible patients, therapy regimen, cycles, effect evaluations, and multidisciplinary treatment. The management of patients with insufficient volume of future liver remnant and patients who cannot achieve R0 resection is the key to the strategies of conversion therapy. Here, we present the resultant evidence- and experience-based consensus to guide the application of neoadjuvant and conversion therapies in clinical practice.
Author Zhao, Hai-Tao
Cai, Jian-Qiang
Author_xml – sequence: 1
  givenname: Hai-Tao
  surname: Zhao
  fullname: Zhao, Hai-Tao
– sequence: 2
  givenname: Jian-Qiang
  surname: Cai
  fullname: Cai, Jian-Qiang
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35068855$$D View this record in MEDLINE/PubMed
BookMark eNp1UU1P3DAQtSpQWaD3nlCOXLJ1bCdOLpXQigISEhc4ImtiT1ivsnawnW359_UKqEqlnubwvjTvHZMD5x0S8rWiSy5F--3n5mm5Y3JphVy2tOk-kQVjVVeyVtADsqgolWXHmTwixzFuKGWc1-wzOeI1bdq2rhfkcbW2DiMW-GvCkArtXUQX51h4Vzj0YDbzDlwqwJk9uMMQbYbSGgNMFmMx-FCscYLkNY7jPEIoNARtnd_CKTkcYIz45e2ekIcfl_er6_L27upmdXFbatGwVGpacUONMcwMlREAwtBG9x1wYWQPchCN7ETFW64H4AxkX3dMaM5Z1-tBDPyEfH_1neZ-i0ajSwFGNQW7hfCiPFj1EXF2rZ78TrWSCiZFNjh_Mwj-ecaY1NbG_T-QO5ijYg1jQrZUVpl69nfWn5D3TjOheSXo4GMMOChtE6TcWo62o6qo2o-n8ngqj6fyeGo_XhbSf4Tv3v-V_AaQ2aIn
CitedBy_id crossref_primary_10_2147_JHC_S483397
crossref_primary_10_3748_wjg_v29_i20_3168
crossref_primary_10_1080_14737140_2024_2346624
crossref_primary_10_1245_s10434_022_12495_z
crossref_primary_10_5582_bst_2022_01019
crossref_primary_10_2147_JHC_S442341
crossref_primary_10_7717_peerj_15950
crossref_primary_10_2147_JHC_S387254
crossref_primary_10_3389_fonc_2022_966821
crossref_primary_10_3389_fonc_2023_1165538
crossref_primary_10_1016_j_hbpd_2022_08_014
crossref_primary_10_1097_JS9_0000000000001879
crossref_primary_10_1186_s12885_024_12816_3
crossref_primary_10_1002_ccr3_7533
crossref_primary_10_2174_1573405620666230908111713
crossref_primary_10_3389_fimmu_2022_913464
crossref_primary_10_3389_fonc_2022_946693
crossref_primary_10_1002_cam4_7105
crossref_primary_10_1097_JS9_0000000000002043
crossref_primary_10_2147_JHC_S447387
crossref_primary_10_1016_j_clinre_2023_102195
crossref_primary_10_2147_JHC_S495059
crossref_primary_10_1186_s12876_023_02661_2
crossref_primary_10_2147_PGPM_S376596
crossref_primary_10_3389_fradi_2022_858963
crossref_primary_10_3389_fphar_2022_998534
crossref_primary_10_1111_cas_16194
Cites_doi 10.1200/JCO.2020.38.15_suppl.4599
10.4254/wjh.v7.i12.1694
10.1007/s00270-017-1874-z
10.3748/wjg.v25.i28.3704
10.1111/ans.14387
10.1245/s10434-018-6653-9
10.1016/j.ijsu.2017.06.082
10.1002/jso.23521
10.1159/000018676
10.21873/anticanres.14479
10.1177/17588359211002720
10.1016/j.clinre.2020.09.002
10.1016/S1665-2681(19)30846-4
10.1001/jamaoncol.2019.0250
10.1055/s-0041-1730949
10.1200/JCO.2021.39.15_suppl.4008
10.1186/s12885-021-08033-x
10.1200/JCO.2021.39.15_suppl.4082
10.1186/s13014-018-1136-5
10.1200/JCO.18.02184
10.1016/j.jhep.2018.02.008
10.1001/jamaoncol.2017.5847
10.1200/JCO.2021.39.15_suppl.e16124
10.20517/2394-5079.2018.20
10.1200/JCO.2021.39.15_suppl.e16178
10.12998/wjcc.v6.i9.259
10.21037/hbsn.2018.08.01
10.1200/JCO.2021.39.3_suppl.335
10.21037/hbsn-20-480
10.1097/MD.0000000000003015
10.1016/j.annonc.2020.10.195
10.1080/00365521.2016.1216588
10.18632/oncotarget.5426
ContentType Journal Article
Copyright The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. 2021
Copyright_xml – notice: The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
– notice: The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. 2021
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DOI 10.3748/wjg.v27.i47.8069
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
DocumentTitleAlternate Zhao HT et al. Consensus on neoadjuvant/conversion therapies for HCC
EISSN 2219-2840
EndPage 8080
ExternalDocumentID PMC8704274
35068855
10_3748_wjg_v27_i47_8069
Genre Journal Article
Review
GroupedDBID ---
123
29R
2WC
36B
53G
5VR
8WL
AAKDD
AAYXX
ACGFO
AENEX
ALMA_UNASSIGNED_HOLDINGS
CCEZO
CHBEP
CIEJG
CITATION
CS3
CW9
DIK
DU5
E3Z
EBS
EJD
F5P
FA0
FRP
GX1
HYE
OK1
P2P
RNS
RPM
TR2
XSB
CGR
CUY
CVF
ECM
EIF
M~E
NPM
7X8
5PM
ID FETCH-LOGICAL-c462t-c013d0ddd2df1d4aa4d06cb9a34d7ba7f467941383cfa32a7b5924c3329bcf4f3
ISSN 1007-9327
2219-2840
IngestDate Thu Aug 21 18:32:03 EDT 2025
Fri Jul 11 03:39:40 EDT 2025
Thu Jan 02 22:56:32 EST 2025
Tue Jul 01 02:11:53 EDT 2025
Thu Apr 24 22:58:38 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed false
IsScholarly true
Issue 47
Keywords Conversion therapy
Neoadjuvant therapy
Hepatocellular carcinoma
Consensus
Language English
License The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c462t-c013d0ddd2df1d4aa4d06cb9a34d7ba7f467941383cfa32a7b5924c3329bcf4f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
Author contributions: Zhao HT was responsible for investigation, writing-original draft, reviewing, and editing; Cai JQ was responsible for conceptualization, supervision, and writing-review and editing; all authors have read and approve the final manuscript.
Corresponding author: Jian-Qiang Cai, MD, Professor, Department of Hepatobiliary Surgery, Cancer Hospital Chinese Academy of Medical Sciences, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing 100021, China. caijianqiang2021@163.com
OpenAccessLink https://pubmed.ncbi.nlm.nih.gov/PMC8704274
PMID 35068855
PQID 2622478071
PQPubID 23479
PageCount 12
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8704274
proquest_miscellaneous_2622478071
pubmed_primary_35068855
crossref_citationtrail_10_3748_wjg_v27_i47_8069
crossref_primary_10_3748_wjg_v27_i47_8069
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-12-21
2021-Dec-21
20211221
PublicationDateYYYYMMDD 2021-12-21
PublicationDate_xml – month: 12
  year: 2021
  text: 2021-12-21
  day: 21
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle World journal of gastroenterology : WJG
PublicationTitleAlternate World J Gastroenterol
PublicationYear 2021
Publisher Baishideng Publishing Group Inc
Publisher_xml – name: Baishideng Publishing Group Inc
References B20
B42
B21
B43
B22
B44
B23
B45
B24
B46
B25
B47
B26
B48
B27
B28
B29
B30
B31
B10
B32
B11
B33
B12
B34
B13
B35
B14
B36
B15
B37
B16
B38
B17
B39
B18
B19
B1
B2
B3
B4
B5
B6
B7
B8
B9
B40
B41
References_xml – ident: B12
– ident: B48
  doi: 10.1200/JCO.2020.38.15_suppl.4599
– ident: B31
  doi: 10.4254/wjh.v7.i12.1694
– ident: B10
– ident: B41
  doi: 10.1007/s00270-017-1874-z
– ident: B9
  doi: 10.3748/wjg.v25.i28.3704
– ident: B24
  doi: 10.1111/ans.14387
– ident: B1
– ident: B27
– ident: B7
– ident: B6
  doi: 10.1245/s10434-018-6653-9
– ident: B29
– ident: B5
  doi: 10.1016/j.ijsu.2017.06.082
– ident: B17
  doi: 10.1002/jso.23521
– ident: B25
– ident: B33
  doi: 10.1159/000018676
– ident: B34
  doi: 10.21873/anticanres.14479
– ident: B38
  doi: 10.1177/17588359211002720
– ident: B43
  doi: 10.1016/j.clinre.2020.09.002
– ident: B16
  doi: 10.1016/S1665-2681(19)30846-4
– ident: B39
  doi: 10.1001/jamaoncol.2019.0250
– ident: B14
  doi: 10.1055/s-0041-1730949
– ident: B20
  doi: 10.1200/JCO.2021.39.15_suppl.4008
– ident: B47
  doi: 10.1186/s12885-021-08033-x
– ident: B45
  doi: 10.1200/JCO.2021.39.15_suppl.4082
– ident: B36
  doi: 10.1186/s13014-018-1136-5
– ident: B8
– ident: B22
  doi: 10.1200/JCO.18.02184
– ident: B11
– ident: B32
  doi: 10.1016/j.jhep.2018.02.008
– ident: B35
  doi: 10.1001/jamaoncol.2017.5847
– ident: B42
  doi: 10.1200/JCO.2021.39.15_suppl.e16124
– ident: B2
– ident: B40
– ident: B21
  doi: 10.20517/2394-5079.2018.20
– ident: B23
  doi: 10.1200/JCO.2021.39.15_suppl.e16178
– ident: B3
  doi: 10.12998/wjcc.v6.i9.259
– ident: B13
  doi: 10.21037/hbsn.2018.08.01
– ident: B4
– ident: B44
– ident: B46
  doi: 10.1200/JCO.2021.39.3_suppl.335
– ident: B28
  doi: 10.21037/hbsn-20-480
– ident: B26
  doi: 10.1097/MD.0000000000003015
– ident: B37
  doi: 10.1016/j.annonc.2020.10.195
– ident: B15
  doi: 10.1080/00365521.2016.1216588
– ident: B18
  doi: 10.18632/oncotarget.5426
– ident: B30
– ident: B19
SSID ssj0023352
Score 2.496665
SecondaryResourceType review_article
Snippet The low resection and high recurrence rates in hepatocellular carcinoma (HCC) are the major challenges to improving prognosis. Neoadjuvant and conversion...
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 8069
SubjectTerms Carcinoma, Hepatocellular - therapy
Consensus
Expert Consensus
Humans
Liver Neoplasms - therapy
Neoadjuvant Therapy - adverse effects
Prognosis
Title Chinese expert consensus on neoadjuvant and conversion therapies for hepatocellular carcinoma
URI https://www.ncbi.nlm.nih.gov/pubmed/35068855
https://www.proquest.com/docview/2622478071
https://pubmed.ncbi.nlm.nih.gov/PMC8704274
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dixMxEA_1fPFFTvyqnhLBF5H0ttns15OI3FHKeSJssQgSssn245Bdabcn-Nc7s8lud-shpy9LSdNsmfllMjOZD0Jeh7ECu8PELMuThIlMj5mKvYRF2gu1MiFP6iSxj5fhZCam82A-GLzrRC3tqmykf92YV_I_XIUx4Ctmyf4DZ9tFYQA-A3_hCRyG5614jM2v821uy_RXGEG-xc4V9Q1AkZfKXO1AUa5c7lpxbX1jb23OFZjIdYzhCg6kqkQHfh2RqrG5UFE6ce3UVhty06kysVTbalNiPc-NLeKEnoUv07ZR19eVqn2wE7VmqSr3Nx118MAUMMk-w2PZdTrwMQZw2ExmK5s4CDoGJ5u9UslvGHPC1Sb-OxDZ2ppOVMae7dFyKMOxHg4Q_ufVcnTNo9FaRKNmar9c9uUneT67uJDp2Ty9Q-5ysBP8xl3jLG5MKMPugs0_s_fU-IbTw_X7eskfxsZhzGxHCUmPyX1nPdD3FgoPyCAvHpJvDgbUwoC2MKBlQTswoAADuocBbWFAAQa0DwPawuARmZ2fpR8mzHXNYFqEvGIalHrjGWO4WYyNUEoY2HZZonxhokxFCzgaE1BdYl8vlM9VlAVgg2vf50mmF2LhPyZHRVnkTwkVfpzDdo3iDC-rcy_BXgHaxEYHWgAlhuS0oZnUrqQ8djb5LsG0RCpLoLIEKkugskQqD8mb9hc_bDmVv8x91bBBgsxDAigg2m4reQiKZxSDdjwkTyxb2tX8ANsoBcGQRD2GtROwnnr_m2K9quuqw9EleCSe3eK9z8m9_bY4IUfVZpe_AO20yl7WCPwNImCXyA
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Chinese+expert+consensus+on+neoadjuvant+and+conversion+therapies+for+hepatocellular+carcinoma&rft.jtitle=World+journal+of+gastroenterology+%3A+WJG&rft.au=Zhao%2C+Hai-Tao&rft.au=Cai%2C+Jian-Qiang&rft.date=2021-12-21&rft.issn=2219-2840&rft.eissn=2219-2840&rft.volume=27&rft.issue=47&rft.spage=8069&rft_id=info:doi/10.3748%2Fwjg.v27.i47.8069&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1007-9327&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1007-9327&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1007-9327&client=summon